Cybin Inc. (NasdaqGM: HELP)
Health Care · Pharmaceuticals · CA
$12.59
+0.96% today · +81.9% 1Y
Cybin Inc. (NasdaqGM: HELP) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $780.38M and employs 100 people.
Over the last twelve months the share price has gained 81.9%, trading between 3.76 and 12.05.
Tweenvest scores Cybin Inc. across four factors: quality 27/100. Its strongest factor is quality.
HELP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $780.38M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.05
- Dividend yield
- —
- Beta (5Y)
- 0.56
- 52-week high
- $12.05
- 52-week low
- $3.76
- Avg volume (3M)
- —
- Shares outstanding
- 61.98M
- Employees
- 100
- Next earnings
- —
About Cybin Inc.
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
- Listed since
- Sep 13, 2019
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.